Novo says Wegovy lowers BMI, obesity rates in children in trial

Novo says Wegovy lowers BMI, obesity rates in children in trial

CNBC • • business

Key Points:

  • Novo released full results from a late-stage trial showing its Wegovy injection significantly reduced BMI in children aged 6 to under 12 with obesity, with a 19.7 percentage point reduction compared to placebo over 68 weeks.
  • The trial included 167 children who also received lifestyle modifications, with over 40% of those treated with Wegovy no longer classified as obese after 68 weeks, assuming continuous treatment.
  • Childhood obesity, affecting an estimated 177 million children worldwide in 2025 and projected to rise, currently has few treatment options for those under 12, making Wegovy’s potential approval for this age group notable.
  • Wegovy’s safety and tolerability in children were consistent with adult trials, with no observed safety concerns related to growth or pubertal development reported in the study.
  • While the trial shows promising short-term results, it does not yet clarify whether early obesity treatment with Wegovy alters long-term disease progression or maintenance into adulthood, highlighting a need for further research.

Trending Business

Trending Technology

Trending Health